| Nplate (romiplostim) / Amgen, Kyowa Kirin |
2013-002564-69: Double-blind, placebo-controlled multicenter phase II trial to evaluate the efficacy and safety of romiplostim for the treatment of chemotherapy-induced low platelet counts in subjects with relapsed ovarian cancer (2nd and 3rd treatment) |
|
|
| Ongoing | 2 | 74 | Europe | Romiplostim, Nplate®, Nplate® | GMIHO Gesellschaft für Medizinische Innovation - Hämatologie und Onkologie mbH, GMIHO Gesellschaft für Medizinische Innovation - Hämatologie und Onkologie mbH, Amgen | Patients with relapsed ovarian cancer (2nd and 3rd line) treated withchemotherapy according to AGO guidelines who developthrombocytopenia grade 3 and/or grade 4. | | | | |
NCT04588194: Romiplostim, Rituximab and Dexamethasone as Frontline Treatment for Immune Thrombocytopenia |
|
|
| Recruiting | 2 | 12 | RoW | Romiplostim, Rituximab, Dexamethasone | David Gomez Almaguer | Immune Thrombocytopenia, Thrombotic Thrombocytopenic Purpura | 11/21 | 11/22 | | |
NCT04371939: Efficacy and Safety of Romiplostim Versus Eltrombopag in the Treatment of Thrombocytopenia in Patients With Wiskott-Aldrich Syndrome |
|
|
| Recruiting | 2 | 30 | RoW | Romiplostim, Nplate, Eltrombopag | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | Wiskott-Aldrich Syndrome | 12/22 | 07/23 | | |
2020-005429-10: Romiplostim for thrombocytopenia induced by lomustine at first progression of MGMT promoter-methylated glioblastoma: a randomized phase II open label multicenter study Romiplostim para el tratamiento de los niveles bajos de plaquetas provocados la quimioterapia con lomustina en pacientes con la primera recurrencia (reaparición del crecimiento) de un tumor cerebral, glioblastoma con metilación de MGMT |
|
|
| Not yet recruiting | 2 | 100 | Europe | romiplostim, [NA], Powder for solution for injection, Nplate | European Organisation for Research and Treatment of Cancer EORTC, EORTC AISBL/IVZW, Amgen Europe B.V., European Organisation for Research and Treatment of Cancer (EORTC) | thrombocytopenia caused by chemotherapy drug lomustine trombocitopenia inducida por lomustina, Low platelets due to bone marrow suppression caused by chemotherapy drug lomustine niveles bajos de plaquetas provocados la quimioterapia con lomustina, Diseases [C] - Blood and lymphatic diseases [C15] | | | | |
RIGOLETTO, NCT04933942: Phase II Trial of Romiplostim for Thrombocytopenia Induced by Lomustine at First Progression of MGMT Promoter-meth Glioblastoma |
|
|
| Withdrawn | 2 | 100 | Europe | Lomustine, Romiplostim | European Organisation for Research and Treatment of Cancer - EORTC, Amgen | First Progression of MGMT Promoter-methylated Glioblastoma | 12/22 | 12/22 | | |
NCT04671901: A Study of Romiplostim to Prevent Low Platelet Counts in Children and Young Adults Receiving Chemotherapy for Solid Tumors |
|
|
| Terminated | 2 | 2 | US | Romiplostim | Memorial Sloan Kettering Cancer Center | Solid Tumor, Solid Tumor, Childhood, Solid Carcinoma | 03/23 | 03/23 | | |
NCT04478123: Using Romiplostim to Treat Low Platelet Counts Following Chemotherapy and Autologous Hematopoietic Cell Transplantation in People With Blood Cancer |
|
|
| Completed | 2 | 62 | US | Romiplostim | Memorial Sloan Kettering Cancer Center, Amgen | Multiple Myeloma, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, HDT-AHCT | 06/23 | 06/23 | | |
NCT02052882: Study of Romiplostim for Chemotherapy Induced Thrombocytopenia |
|
|
| Completed | 2 | 60 | US | romiplostim | Memorial Sloan Kettering Cancer Center, Amgen | Isolated Chemotherapy-induced Thrombocytopenia | 11/23 | 11/23 | | |
NCT06345495: High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly |
|
|
| Not yet recruiting | 2 | 30 | US | Ruxolitinib, Jakafi, INCB018424, INC424, Allogeneic Stem Cell Transplantation, Autologous stem cell transplant, Cord Blood, Levetiracetam, Eltrombopag, Promacta®, Busulfan, Busulfex™, Myleran®, Romiplostim, AMG 531, Nplate, Fludarabine phosphate, Fludarabine, Fludara®, Cyclophosphamide, Cytoxan®, Neosar®, Mesna, Mesnex™, Tacrolimus, Prograf® | M.D. Anderson Cancer Center, Incyte Corporation | Splenomegaly, Myelofibrosis | 01/27 | 01/29 | | |
NCT05323617: Efficacy of Romiplostim in Treatment of SAA in Adults Previously Untreated With or Refractory to Immunosuppressive Therapy |
|
|
| Withdrawn | 2 | 40 | NA | Romiplostim, Nplate®, Antithymocyte Globulin, Cyclosporine A | Amgen | Severe Aplastic Anemia (SAA) | 02/25 | 02/25 | | |
NCT04673266: Using Romiplostim to Treat Low Platelet Counts During Chemotherapy in People With Lymphoma |
|
|
| Active, not recruiting | 2 | 11 | US | Romiplostim | Memorial Sloan Kettering Cancer Center, Amgen, Tel-Aviv Sourasky Medical Center | Lymphoma Patients, Thrombocytopenia | 12/25 | 12/25 | | |
ChiCTR-OPC-15007012: Evaluating the Pharmacokinetics and Pharmacodynamics of Romiplostim in Patients with Immune Thrombocytopenia |
|
|
| Recruiting | 1/2 | 24 | | Romiplostim: 1ug/kg ;Romiplostim: 3ug/kg ;Romiplostim: 6ug/kg | Chinese Academy of Medical Science Hematology Hospital; Kyowa Hakko Kirin China Pharmaceutical CO., Ltd., self financing | Chronic Idiopatic Thrombocytopenic Purpura(ITP) | | | | |
